Eribulin (mesylate)

Eribulin (E7389) mesylate is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin mesylate inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules.

Product Specifications

CAS Number

[441045-17-6]

Product Name Alternative

B1939 (mesylate) ; E7389 (mesylate) ; ER-086526 (mesylate)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Microtubule/Tubulin

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/eribulin-mesylate.html

Purity

99.91

Solubility

DMSO : ≥ 100 mg/mL

Smiles

C=C1C[C@@](CC[C@@]2(C[C@@]3([H])O4)O[C@]([C@](O[C@](C5)([H])CC6)([H])[C@@]6([H])O7)([H])[C@@]4([H])[C@]7([H])[C@@]3([H])O2)([H])O[C@@]1([H])CC[C@](C[C@@H](C)C8=C)([H])O[C@]8([H])C[C@@](O[C@H](C[C@H](O)CN)[C@@H]9OC)([H])[C@]9([H])CC5=O.CS(=O)(O)=O

Molecular Formula

C41H63NO14S

Molecular Weight

826.00

Precautions

H302, H315, H319, H335

References & Citations

[1]Okouneva, T., et al., Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther, 2008. 7 (7) : p. 2003-11.|[2]Smith, J.A., et al., Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry, 2010. 49 (6) : p. 1331-7.|[3]Towle, M.J., et al., Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res, 2011. 71 (2) : p. 496-505.|[4]Watanabe K, et, al. Low-dose eribulin reduces lung metastasis of osteosarcoma in vitro and in vivo. Oncotarget. 2019 Jan 4; 10 (2) : 161-174.